TIM-3 Expression on Dendritic Cells in Colorectal Cancer

TIM-3 was originally identified as a negative regulator of helper T cells and is expressed on dendritic cells (DCs). Since the inhibition of TIM-3 on DCs has been suggested to enhance T cell-mediated anti-tumor immunity, we examined its expression on DCs within the tumor microenvironment (TME) in co...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-05, Vol.16 (10), p.1888
Main Authors: Sakuma, Mei, Katagata, Masanori, Okayama, Hirokazu, Nakajima, Shotaro, Saito, Katsuharu, Sato, Takahiro, Fukai, Satoshi, Tsumuraya, Hideaki, Onozawa, Hisashi, Sakamoto, Wataru, Saito, Motonobu, Saze, Zenichiro, Momma, Tomoyuki, Mimura, Kosaku, Kono, Koji
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Cancer
Cancer therapies
Cell-mediated immunity
Chemotherapy
Clinical trials
Colorectal cancer
Colorectal carcinoma
Dendritic cells
Diagnostic reagents industry
Flow cytometry
Genes
Health aspects
Immunohistochemistry
Immunotherapy
Infiltration
Invasiveness
Ligands
Lymphocytes
Lymphocytes T
Medical prognosis
Metastases
Patients
Radiation therapy
Technology
Transcriptomics
Tumor microenvironment
Tumors
Western blotting
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TIM-3 was originally identified as a negative regulator of helper T cells and is expressed on dendritic cells (DCs). Since the inhibition of TIM-3 on DCs has been suggested to enhance T cell-mediated anti-tumor immunity, we examined its expression on DCs within the tumor microenvironment (TME) in colorectal cancer (CRC) using transcriptomic data from a public database ( = 592) and immunohistochemical evaluations from our cohorts of CRC ( = 115). The expression of TIM-3 on DCs in vitro was examined by flow cytometry, while the expression of its related molecules, cGAS and STING, on immature and mature DCs was assessed by Western blotting. The expression of (TIM-3) was strongly associated with the infiltration of DCs within the TME of CRC. Immunohistochemical staining of clinical tissue samples revealed that tumor-infiltrating DCs expressed TIM-3; however, their number at the tumor-invasive front significantly decreased with stage progression. TIM-3 expression was higher on immature DCs than on mature DCs from several different donors ( = 6). Western blot analyses showed that the expression of STING was higher on mature DCs than on immature DCs, which was opposite to that of TIM-3. We demonstrated that TIM-3 was highly expressed on tumor-infiltrating DCs of CRC and that its expression was higher on immature DCs than on mature DCs.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16101888